Oculis Holding AG (OCS)
OCS Stock Price Chart
Explore Oculis Holding AG interactive price chart. Choose custom timeframes to analyze OCS price movements and trends.
OCS Company Profile
Discover essential business fundamentals and corporate details for Oculis Holding AG (OCS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 May 2021
Employees
49.00
Website
https://oculis.comCEO
Riad Sherif
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Financial Timeline
Browse a chronological timeline of Oculis Holding AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.50, while revenue estimate is $225.20K.
Earnings released on 21 Aug 2025
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%, while revenue for the quarter reached $328.96K , beating expectations by +129.50%.
Earnings released on 8 May 2025
EPS came in at -$0.77 falling short of the estimated -$0.51 by -50.98%, while revenue for the quarter reached $321.94K , beating expectations by +47.99%.
Earnings released on 11 Mar 2025
EPS came in at -$0.76 falling short of the estimated -$0.48 by -58.33%, while revenue for the quarter reached $3.30K , missing expectations by -97.71%.
Earnings released on 7 Nov 2024
EPS came in at -$0.55 falling short of the estimated -$0.52 by -5.77%, while revenue for the quarter reached $236.01K , missing expectations by -9.23%.
Earnings released on 27 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.43 by -30.23%, while revenue for the quarter reached $273.44K , beating expectations by +0.54%.
Earnings released on 8 May 2024
EPS came in at -$0.44 falling short of the estimated -$0.41 by -7.32%, while revenue for the quarter reached $245.15K , missing expectations by -15.07%.
Earnings released on 18 Mar 2024
EPS came in at -$0.38 surpassing the estimated -$0.42 by +9.52%, while revenue for the quarter reached $216.21K , missing expectations by -23.02%.
Earnings released on 15 Nov 2023
EPS came in at -$0.38 falling short of the estimated -$0.36 by -5.56%, while revenue for the quarter reached $238.78K , beating expectations by +97.45%.
Earnings released on 29 Aug 2023
EPS came in at -$0.38 falling short of the estimated -$0.33 by -15.15%, while revenue for the quarter reached $278.72K , beating expectations by +42.62%.
Earnings released on 31 Mar 2023
EPS came in at -$1.51 , while revenue for the quarter reached $261.36K .
Earnings released on 28 Mar 2023
EPS came in at -$0.30 , while revenue for the quarter reached $231.38K .
Earnings released on 30 Sept 2022
EPS came in at -$0.31 , while revenue for the quarter reached $205.28K .
Earnings released on 30 Jun 2022
EPS came in at -$0.39 , while revenue for the quarter reached $250.53K .
Earnings released on 31 Mar 2022
EPS came in at -$0.32 , while revenue for the quarter reached $267.89K .
Earnings released on 31 Dec 2021
EPS came in at -$0.19 , while revenue for the quarter reached $423.21K .
Earnings released on 30 Sept 2021
EPS came in at -$0.16 , while revenue for the quarter reached $21.48K .
OCS Stock Performance
Access detailed OCS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.